Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Mark D. Pescovitz(University Medical Center), Frances C. Brown(Roche (United Kingdom)), Robert M. Merion(University of Kansas Medical Center), Kristina Wren(Center for Global Development), Ludger Banken(Roche (Switzerland)), Richard B. Freeman(Harvard University Press), William Buhles(Unknown), John O'Grady(St James's University Hospital), John D. Pirsch(University of Wisconsin–Madison), Carlos V. Payá(Unknown), Zung To(Center for Global Development), Charles A. Robinson(Center for Global Development), John M. Rabkin(Oregon Health & Science University)
Cited by 363
Related Papers
Sjögren's syndrome. Proposed criteria for classification
|Arthritis & Rheumatism|1986|685
Kidney Transplantation as Primary Therapy for End-Stage Renal Disease
|Clinical Journal of the American Society of Nephrology|2008|606
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
|The Lancet|1997|501
Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant
|New England Journal of Medicine|1999|485
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
|New England Journal of Medicine|2002|394